CellGenix GmbH

Industrial Impact

Chimeron Bio | January 25, 2022

Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan to expand operations in the Philadelphia area and move to The Curtis, a landmark site in Center City Philadelphia under BioLabs, the leading developer and operator of life science co-working spaces in the U.S. and internationally. The move stems from Chimeron’s need for an expanded footprint to accommodate its growing R&D team and operations....

Research

Celyad Oncology SA | December 09, 2021

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Research

Selvita | February 07, 2022

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Medical

NiKang Therapeutics | May 31, 2021

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...